Search This Blog

Monday, May 6, 2019

Aclaris Therapeutics initiated at SVB Leerink

Aclaris Therapeutics initiated with an Outperform at SVB Leerink. SVB Leerink analyst Pasha Sarraf initiated Aclaris Therapeutics with an Outperform rating and $13 price target.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)